Net Margin: Passage Bio (PASG)

Passage Bio, Inc. (PASG) is developing gene therapies for the treatment of CNS pathologies while awaiting FDA approval. The net profit margin on the GURU.Markets chart confirms a trend where the current level is 0.00. The business model relies on outsourcing vector production to reduce costs, although the company faces a liquidity shortage due to expensive research.
Comprehensive metric breakdowns and analytics for passagebio.com (PASG)

Outsourcing vector production to external CDMO partners minimizes capital expenditures for Passage Bio, Inc. (PASG). Net profit margin measures the portion of net income in every dollar of revenue, reflecting the overall efficiency of the business. By analyzing this net margin chart, an investor identifies the company's ability to generate income after all expenses. Sharp fluctuations on the net margin chart often signal one-time operations. The stability of this indicator confirms the fundamental resilience of the asset.